United Therapeutics
UTHR
319 hedge funds and large institutions have $6.8B invested in United Therapeutics in 2014 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 92 increasing their positions, 145 reducing their positions, and 36 closing their positions.
350% more funds holding in top 10
Funds holding in top 10: 4 → 18 (+14)
47% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 36
46% more capital invested
Capital invested by funds: $4.66B → $6.8B (+$2.14B)
5% more funds holding
Funds holding: 303 → 319 (+16)
37% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 145
72% less call options, than puts
Call options by funds: $92.8M | Put options by funds: $331M
Top Buyers
| 1 |
SCM
Scopia Capital Management
New York
|
+$209M |
| 2 |
AC
Amici Capital
New York
|
+$97.3M |
| 3 |
Millennium Management
New York
|
+$83.2M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$79.7M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$59.9M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$77.3M |
| 2 |
JP Morgan Chase
New York
|
-$50M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$44M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.6M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$36.9M |
UTHR Hedge Fund Activity: Q3 2014 in Review
319 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2014, worth a combined $6.8B — up 46% from $4.66B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new UTHR positions and 36 closed out — a net gain of 17 holders — while 92 added to existing stakes and 145 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $209M. The largest seller was Deutsche Bank, cutting an estimated $77.3M.
- 319 institutional investors held United Therapeutics (UTHR) as of Q3 2014, up from 303 in Q2 2014.
- Funds reported $6.8B of United Therapeutics stock for Q3 2014, up 46% quarter-over-quarter.
- 53 funds opened new United Therapeutics positions in Q3 2014 and 36 closed out, a net change of +17 holders.
- The largest United Therapeutics buyer in Q3 2014 was Scopia Capital Management, an estimated $209M added.
- The largest United Therapeutics seller in Q3 2014 was Deutsche Bank, an estimated $77.3M sold.
Based on aggregated 13F filings for Q3 2014.